GlassScriptPhysician profile
Geary D Smith
NPI 1336406180
$443.50
in general payments reported to CMS, 2019-2025
19 companies · $111 in 2025
The $111 reported for 2025 was more than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.08 · 2022: $54.91 · 2023: $106 · 2024: $144 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $56.92 | 2023-2024 | Ozempic, Rybelsus |
| Amgen INC. | $51.65 | 2021-2024 | Otezla, Repatha, Prolia |
| Lilly USA, LLC | $32.43 | 2023-2024 | Mounjaro |
| Glaxosmithkline, LLC. | $31.48 | 2024 | Shingrix, Arexvy |
| Alnylam Pharmaceuticals INC. | $25.71 | 2023 | Givlaari |
| Sanofi Pasteur INC. | $24.37 | 2025 | |
| Lundbeck LLC | $24.18 | 2023 | Vyepti |
| Phathom Pharmaceuticals, INC. | $22.24 | 2024-2025 | Voquezna |
| Seqirus USA INC | $22.21 | 2025 | Flucelvax, Fluad |
| Tolmar, INC. | $20.39 | 2025 | Jatenzo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.86 | 2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $16.71 | 2022 | |
| Radius Health, INC. | $16.52 | 2025 | Tymlos |
| Janssen Pharmaceuticals, INC | $15.17 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.00 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.25 | 2024 | |
| Pfizer INC. | $12.74 | 2023 | |
| Optinose US, INC. | $11.72 | 2022 | |
| Sumitomo Pharma America, INC. | $10.95 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geary Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.